Alkermes Announces CEO Succession and Leadership Transition Plan

Alkermes ( (ALKS) ) just unveiled an update.

Alkermes plc announced on Feb. 25, 2026 that long-serving Chief Executive Officer Richard Pops will retire from the CEO role on July 31, 2026 after 35 years at the helm, while remaining non-executive chairman and senior advisor through year-end to provide continuity. The board has appointed current Executive Vice President and Chief Operating Officer Blair Jackson, a 25-year company veteran with broad scientific and operational experience, to succeed him as CEO effective Aug. 1, 2026, in a planned succession that aims to maintain strategic momentum in neuroscience, particularly in sleep medicine and orexin-based therapies, following the recent Avadel acquisition.

Pops’ transition is structured with detailed compensation and equity-vesting terms designed to retain his guidance during the handover and beyond his board tenure, underscoring the board’s emphasis on stability during a pivotal growth phase for the company. Jackson’s elevation, following his key role in recent portfolio reshaping and transactions, signals continuity in Alkermes’ strategy to build on its commercial base in serious mental illness and addiction while accelerating its expansion into narcolepsy and related central nervous system disorders, a direction closely watched by investors and partners.

The most recent analyst rating on (ALKS) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Alkermes stock, see the ALKS Stock Forecast page.

Spark’s Take on ALKS Stock

According to Spark, TipRanks’ AI Analyst, ALKS is a Outperform.

The score is driven primarily by strong financial performance (high margins, low leverage, and strong cash conversion) and a constructive earnings update with raised guidance and solid product growth. Valuation looks reasonable on a 14.644 P/E, while technicals are mixed due to a slightly negative MACD and elevated stochastic despite price holding above key moving averages.

To see Spark’s full report on ALKS stock, click here.

More about Alkermes

Alkermes plc is a global biopharmaceutical company focused on developing innovative neuroscience medicines, with a portfolio of proprietary commercial products for alcohol and opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Headquartered in Ireland with operations in the U.S., it is advancing late-stage candidates for narcolepsy and idiopathic hypersomnia and orexin 2 receptor agonists for other neurological disorders.

The company has more than 2,000 employees, generates about $1.5 billion in annual revenue primarily from its own medicines, and recently expanded its presence in sleep medicine through the acquisition of Avadel Pharmaceuticals. Its pipeline targets central disorders of hypersomnolence and other complex neurological conditions, reinforcing its position as an innovation-driven neuroscience player.

Average Trading Volume: 1,855,221

Technical Sentiment Signal: Strong Buy

Current Market Cap: $5.51B

For detailed information about ALKS stock, go to TipRanks’ Stock Analysis page.